October, 15 2008, 05:04pm EDT

For Immediate Release
Contact:
EWG Public Affairs, (202) 667-6982 or (202) 441-6214
Bottled Water Lobby's Misinformation Campaign
IBWA Claims Tests Show No Contaminants, But Test Results Nowhere to Be Found
WASHINGTON
Yesterday, the lobby group for the bottled water industry used
untruths, misleading statements and claims that were outright wrong in
its attempt to dispel a study by Environmental Working Group (EWG) that found harmful chemicals in a number of popular U.S. brands.
Unfortunately, the list of false and misleading statements made by
the International Bottled Water Association (IBWA) is rather long, but
EWG prides itself on using the most accurate data in its research and
setting the record straight with most accurate information available.
IBWA: EWG tests show that two bottled water samples did not meet a California state standard for one regulated substance.
Fact: EWG tests show that three bottled water samples from two
cities exceeded limits for known and suspected carcinogens set by
California's Safe Drinking Water and Toxic Enforcement Act (also known
as Proposition 65) and the California health code on two counts:
- One chemical, bromodichloromethane, which the U.S. Environmental
Protection Agency has labeled a known carcinogen and which was found at
levels three to five times higher than California's Proposition 65
safety standard. - A family of chemicals, trihalomethanes, which the EPA, California
authorities and other governmental and international bodies consider
cancer-causing by-products of municipal water treatment.
IBWA: The California requirement for trihalomethanes is eight
times lower than the U.S. Food and Drug Administration (FDA) standard
of quality for bottled water and the EPA maximum contaminant level for
tap water.
Fact: The California safety standard for trihalomethanes is
more protective of California citizens than federal standards set more
than a decade ago. The EPA says that consumption of chemicals in this
family poses a risk for potential health effects, including "liver,
kidney or central nervous system problems; increased risk of cancer."
IBWA appears to have shifted its position overnight. Its initial
statement, above, released October 14, suggested that California's
safety standard for trihalomethanes is too high. But the next day, Joe
Doss, president of the International Bottled Water Association, was
quoted by MS-NBC as saying he would not defend any company that is
exceeding the standard in California. "If they have exceeded it, they
should meet it," he said, according to MS-NBC.
IBWA: The EWG report is based on the faulty premise that if
any substance is present in a bottled water product, even if it does
not exceed the established regulatory limit or no standard has been
set, then it's a health concern.
Fact: The EWG report clearly identifies the levels of
pollutants detected in bottled water samples and the federal and state
legal standards for those pollutants, but it also acknowledges that the
health effects of life-long exposure to this mixture of pollutants are
not known. EWG's position is that consumers have a right to know about
all the contaminants present in bottled water.
IBWA: EWG claims that the presence of bacteria, measured by
the HPC (heterotrophic plate count) method, is a contaminant. But these
levels did not exceed any state or federal standard, and bacteria are
commonly found at these same levels in many foods, with no adverse
health consequences.
Fact: EPA clearly states on its Safewater website
that the presence of bacteria, measured by the HPC method, serves as an
indicator of the overall hygiene at the production site. EWG measured
bacteria in the context of EPA's judgment that "the lower the
concentration of bacteria in drinking water, the better maintained the
water system is."
IBWA: The IBWA Code of Practice limit for trihalomethanes is
the same as the California standard. However, neither of the two brands
mentioned by the EWG was made by IBWA members. The decision to set the
IBWA standard at this level was made to ensure that IBWA members who
complied with its Code of Practice requirements would meet all state
and federal bottled water regulations.
Fact: This argument is simply spurious. IBWA cannot have it
both ways. It is consumer deception to say that IBWA members must meet
the 10 parts-per-billion California standard for trihalomethanes but
that it is perfectly fine for producers who are not members to sell a
product that fails the standard, in these cases quite dramatically. The
state of California has conducted rigorous risk assessments that are
the foundation of its drinking water standards. By adopting them, the
IBWA is implicitly endorsing the science that supports them and the
state of California's judgment that higher levels pose cancer risks
sufficient to require a warning under state law. The notion put forth
by IBWA that this standard is arbitrary and that outside of California
only bottled water produced by member companies must comply would be
laughable if it were not for the fact that the contaminants in question
are serious cancer-causing compounds. EWG welcomes IBWA's adoption of
the California standard for its own members. But until all IBWA members
label their products as complying with the high California/IBWA
standard, consumers have no idea whether they are buying a product made
by an IBWA member.
IBWA: IBWA supports a consumer's right to clear, accurate and
comprehensive information about the bottled water products they
purchase. All packaged foods and beverages, including bottled water,
are subject to extensive FDA labeling requirements that provide
consumers with a great deal of product quality information. In
addition, virtually all bottled water products include a phone number
on the label that consumers can use to contact the company.
Fact: It is not sufficient or relevant for bottled water to
meet the same standards as cookies and cake mix. Bottled water should
be held to the same disclosure provisions as tap water. Bottlers should
disclose on the label the source of the water, the specific filtration
method used, the frequency and type of contaminant testing conducted
and the results.
IBWA: Consumers should search for information not on the
label via a request to the bottler, and if the bottler declines to
provide that information, the consumer can choose another brand.
Fact: The IBWA's position is the same as EWG's: Buyer Beware
IBWA: Bottled water is not simply tap water in a bottle.
Bottled water companies that use municipal source water often treat and
purify the water, employing processes such as reverse osmosis and
distillation before it is bottled and delivered to consumers as a
packaged food product. The product will be labeled as "purified water,"
or alternatively, "reverse osmosis water" if it is treated by reverse
osmosis or "distilled water" if it treated by distillation. If bottled
water is sourced from a municipal water system and has not been further
treated, FDA requires the label to state that it is from a municipal or
community water system.
Fact: Consumers need to know the precise source of the water
they drink and the results of all contaminant testing. Simply naming a
type of treatment means nothing to the average consumer. By claiming to
use treatment, the companies can avoid disclosing the source of their
water. And there is nothing in the FDA rules to guarantee that the
bottler has used high-quality, effective treatment.
IBWA: In addition to federal and state regulations, members
of the International Bottled Water Association (IBWA) are required to
adhere to standards in the IBWA Bottled Water Code of Practice that, in
several cases, are stricter than FDA and state bottled water
regulations. The IBWA Bottled Water Code of Practice is enforced
through a mandatory, annual, unannounced plant inspection by an
independent, third party organization.
Fact: EWG supports IBWA's efforts to promote stricter
standards. But the IBWA does not represent the entire bottled water
industry and cannot vouch for the safety and purity of bottled water
produced by non-IBWA members. Since labels do not routinely disclose
IBWA membership, the consumer has no way to distinguish brands that
adhere to IBWA standards from those that do not.
IBWA: EWG was critical of the bottled water brands found to
contain fluoride, although the levels of fluoride found in the bottled
water tested by the EWG were in compliance with the FDA standards.
Fact: Neither the FDA nor other authorities offer a
one-size-fits-all safety standard for fluoride. The U.S. Centers for
Disease Control and Prevention warns that babies and young children who
consume too much fluoride can develop a form of permanent tooth damage
called enamel fluorosis and estimates that 1/3 of U.S. children 15 and
younger have this condition. CDC cautions against mixing infant formula concentrate with fluoridated water.
The American Academy of Pediatrics warns against giving fluoridated drinking water to infants younger than six months, and the American Dental Association
recommends formula made with fluoride-free water for babies less than 1
year old. Bottled water brands that do not disclose the presence of
fluoride deprive consumers of their right to know what is in the water
they buy for themselves and their families.
And finally, can the FDA ensure bottled water quality and purity? Not so much.
EWG's Investigation found that the FDA has rarely inspected
bottled water plants - and if it has, to date it has not published the
results. FDA's website acknowledges that "bottled water plants
generally are assigned low priority for inspection."
FDA regulations require bottled water manufacturers to test their
product once a week for microbiological contamination but only once a
year for chemical contaminants and once every four years for
radiological contamination. Bottlers that process and package tap water
can obtain a waiver of federal testing requirements by submitting the
water quality report from the municipal water supply that is the basis
for their product.
NOTE: The IBWA recently brought on board Tom Lauria, formerly
the top spin doctor for the tobacco industry. We detect Mr. Lauria's
fingerprints on IBWA's rebuttal to EWG's scientific testing. In our
view, he has had extensive experience distorting the facts and
misleading consumers in an attempt to hide the truth about the industry
that pays his salary.
What is IBWA trying to hide?
From the IBWA's website:
"The career of Tom Lauria, the new vice president for communications
of the International Bottled Water Association (IBWA), spans 25 years
in some of the more challenging media relations and public affairs jobs
- such as work he did for The Tobacco Institute.... In his new position,
Lauria oversees the editorial content for IBWA's Web site, IBWA's
Bottled Water Reporter bimonthly magazine and the weekly e-mail news
alert Splash. He also is responsible for development of IBWA's public
affairs outreach." IBWA, June 2008
The Environmental Working Group is a community 30 million strong, working to protect our environmental health by changing industry standards.
(202) 667-6982LATEST NEWS
Critics Shred JD Vance as He Shrugs Off Millions of Americans Losing Medicaid as 'Minutiae'
"What happened to you J.D. Vance—author of Hillbilly Elegy—now shrugging off Medicaid cuts that will close rural hospitals and kick millions off healthcare as 'minutiae?'" asked Rep. Ro Khanna (D-Calif.).
Jul 01, 2025
Vice President J.D. Vance took heat from critics this week when he downplayed legislation that would result in millions of Americans losing Medicaid coverage as mere "minutiae."
Writing on X, Vance defended the budget megabill that's currently being pushed through the United States Senate by arguing that it will massively increase funding to Immigration and Customs Enforcement, which he deemed to be a necessary component of carrying out the Trump administration's mass deportation operation.
"The thing that will bankrupt this country more than any other policy is flooding the country with illegal immigration and then giving those migrants generous benefits," wrote Vance. "The [One Big Beautiful Bill] fixes this problem. And therefore it must pass."
He then added that "everything else—the CBO score, the proper baseline, the minutiae of the Medicaid policy—is immaterial compared to the ICE money and immigration enforcement provisions."
It was this line that drew the ire of many critics, as the Congressional Budget Office has estimated that the Senate version of the budget bill would slash spending on Medicaid and the Children's Health Insurance Program by more than $1 trillion over a ten-year-period, which would result in more than 10 million people losing their coverage. Additionally, Sen. Rick Scott (R-Fla.) has proposed an amendment that would roll back the expansion of Medicaid under the 2010 Affordable Care Act, which would likely kick millions more off of the program.
Many congressional Democrats were quick to pounce on Vance for what they said were callous comments about a vital government program.
"So if the only thing that matters is immigration... why didn't you support the bipartisan Lankford-Murphy bill that tackled immigration far better than your Ugly Bill?" asked Rep. Daniel Goldman (D-N.Y.). "And it didn't have 'minutiae' that will kick 12m+ Americans off healthcare or raise the debt by $4tn."
"What happened to you J.D. Vance—author of Hillbilly Elegy—now shrugging off Medicaid cuts that will close rural hospitals and kick millions off healthcare as 'minutiae?'" asked Rep. Ro Khanna (D-Calif.).
Veteran healthcare reporter Jonathan Cohn put some numbers behind the policies that are being minimized by the vice president.
"11.8M projected to lose health insurance," he wrote. "Clinics and hospitals taking a hit, especially in rural areas. Low-income seniors facing higher costs. 'Minutiae.'"
Activist Leah Greenberg, the co-chair of progressive organizing group Indivisible, zeroed in on Vance's emphasis on ramping up ICE's funding as particularly problematic.
"They are just coming right out and saying they want an exponential increase in $$$ so they can build their own personal Gestapo," she warned.
Washington Post global affairs columnist Ishaan Tharoor also found himself disturbed by the sheer size of the funding increase for ICE that Vance is demanding and he observed that "nothing matters more apparently than giving ICE a bigger budget than the militaries of virtually every European country."
Keep ReadingShow Less
'Heinrich Should Be Ashamed': Lone Senate Dem Helps GOP Deliver Big Pharma Win
The provision, part of the Senate budget bill, was described as "a blatant giveaway to the pharmaceutical industry that would keep drug prices high for patients while draining $5 billion in taxpayer dollars."
Jul 01, 2025
The deep-pocketed and powerful pharmaceutical industry notched a significant victory on Monday when the Senate parliamentarian ruled that a bill described by critics as a handout to drug corporations can be included in the Republican reconciliation package, which could become law as soon as this week.
The legislation, titled the Optimizing Research Progress Hope and New (ORPHAN) Cures Act, would exempt drugs that treat more than one rare disease from Medicare's drug-price negotiation program, allowing pharmaceutical companies to charge exorbitant prices for life-saving medications in a purported effort to encourage innovation. (Medications developed to treat rare diseases are known as "orphan drugs.")
The consumer advocacy group Public Citizen observed that if the legislation were already in effect, Medicare "would have been barred from negotiating lower prices for important treatments like cancer drugs Imbruvica, Calquence, and Pomalyst."
Among the bill's leading supporters is Sen. Martin Heinrich (D-N.M.), whose spokesperson announced the parliamentarian's decision to allow the measure in the reconciliation package after previously advising that it be excluded. Heinrich is listed as the legislation's only co-sponsor in the Senate, alongside lead sponsor Sen. John Barrasso (R-Wyo.).
"Sen. Heinrich should be ashamed of prioritizing drug corporation profits over lower medicine prices for seniors and people with disabilities," Steve Knievel, access to medicines advocate at Public Citizen, said in a statement Monday. "Patients and consumers breathed a sigh of relief when the Senate parliamentarian stripped the proposal from Republicans' Big Ugly Betrayal, so it comes as a gut punch to hear that Sen. Heinrich welcomed the reversal and continued to champion a proposal that will transfer billions from taxpayers to Big Pharma."
"People across the country are demanding lower drug prices and for Medicare drug price negotiations to be expanded, not restricted," Knievel added. "Sen. Heinrich should apologize to his constituents and start listening to them instead of drug corporation lobbyists."
The Biotechnology Innovation Organization, a lobbying group whose members include pharmaceutical companies, has publicly endorsed and promoted the legislation, urging lawmakers to pass it "as soon as possible."
"This is a blatant giveaway to the pharmaceutical industry that would keep drug prices high for patients."
The nonpartisan Congressional Budget Office has estimated that the ORPHAN Cures Act would cost U.S. taxpayers around $5 billion over the next decade.
Merith Basey, executive director of Patients For Affordable Drugs Now, said that "patients are infuriated to see the Senate cave to Big Pharma by reviving the ORPHAN Cures Act at the eleventh hour."
"This is a blatant giveaway to the pharmaceutical industry that would keep drug prices high for patients while draining $5 billion in taxpayer dollars," said Basey. "We call on lawmakers to remove this unnecessary provision immediately and stand with an overwhelming majority of Americans who want the Medicare Negotiation program to go further. Medicare negotiation will deliver huge savings for seniors and taxpayers; this bill would undermine that progress."
Keep ReadingShow Less
Trump-Musk Gutting of USAID Could Lead to More Than 14 Million Deaths Over Five Years: Study
"For many low and middle income countries, the resulting shock would be comparable in scale to a global pandemic or a major armed conflict," said the coordinator behind the study.
Jul 01, 2025
A study published Monday by the medical journal The Lancet found that deep funding cuts to the U.S. Agency for International Development, a main target of the Department of Government Efficiency's government-slashing efforts, could result in more than 14 million additional deaths by the year 2030.
For months, humanitarian programs and experts have sounded the alarm on the impact of cutting funding for the U.S. Agency for International Development (USAID), which is the largest funding agency for humanitarian and development aid around the globe, according to the study.
"Our analysis shows that USAID funding has been an essential force in saving lives and improving health outcomes in some of the world's most vulnerable regions over the past two decades," said Daniella Cavalcanti, postdoctoral researcher at the Institute of Collective Health and an author of the study, according to a statement published Tuesday. Between 2001 and 2021, an estimated 91 million deaths were prevented in low and middle income countries thanks programs supported by USAID, according to the study.
The study was coordinated by researchers from the Barcelona Institute for Global Health with the help of the Institute of Collective Health of the Federal University of Bahia, the University of California Los Angeles, and the Manhiça Centre for Health Research, as well as others.
To project the future consequences of USAID funding cuts and arrive at the 14 million figure, the researchers used forecasting models to simulate the impact of two scenarios, continuing USAID funding at 2023 levels versus implementing the reductions announced earlier this year, and then comparing the two.
Those estimated 14 million additional deaths include 4.5 million deaths among children younger than five, according to the researchers.
The journalist Jeff Jarvis shared reporting about the study and wrote "murder" on X on Tuesday.
In March, Secretary of State Marco Rubio announced that the 83% of the programs at USAID were being canceled. In the same post on X, he praised the Department of Government Efficiency, which at that point had already infiltrated the agency. "Thank you to DOGE and our hardworking staff who worked very long hours to achieve this overdue and historic reform," he wrote.
Davide Rasella, research professor at Barcelona Institute for Global Health and coordinator of the study, said in a statement Tuesday that "our projections indicate that these cuts could lead to a sharp increase in preventable deaths, particularly in the most fragile countries. They risk abruptly halting—and even reversing—two decades of progress in health among vulnerable populations. For many low- and middle-income countries, the resulting shock would be comparable in scale to a global pandemic or a major armed conflict."
One country where USAID cuts have had a particularly deadly impact is Sudan, according to The Washington Post, which reported on Monday that funding shortages have led to lack of medical supplies and food in the war-torn nation.
"There's a largely unspoken and growing death toll of non-American lives thanks to MAGA," wrote Ishaan Tharoor, a Post columnist, of the paper's reporting on Sudan.
In reference to the reporting on Sudan, others laid blame on billionaire Elon Musk, the billionaire and GOP mega-donor who was initially tapped to lead the Department of Government Efficiency.
"In a less imperfect world, Musk and [President Donald] Trump would be forever cast as killers of children, and this would be front-page news for months and the subject of Sunday sermons in every church," wrote the journalist David Corn.
Keep ReadingShow Less
Most Popular